Physician profile
Kaylee L Vantrease
NPI 1558635508
$833.46
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $503.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $266.22 | 2021-2022 | |
| Lilly USA, LLC | $118.86 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.51 | 2022 | |
| Janssen Pharmaceuticals, INC | $72.82 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $65.50 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.31 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $36.49 | 2021-2022 | |
| Novo Nordisk INC | $23.60 | 2022 | |
| Sanofi Pasteur INC. | $21.80 | 2021 | |
| Glaxosmithkline, LLC. | $20.95 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.23 | 2022 | |
| Mylan Specialty L.P. | $20.04 | 2021 | |
| Genentech USA, INC. | $15.61 | 2021 | |
| Phadia US INC. | $12.52 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylee Vantrease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.